FindTrial
Sign In

Survey regarding clinical and demographic characteristics of Japanese NVAF patient treated with warfarin and physicians treatment strategies to them in general practice.

Survey regarding clinical and demographic characteristics of Japanese NVAF patient treated with warfarin and physicians treatment strategies to them in general practice. - SELECT study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000024531
Enrollment
300
Registered
2016-10-27
Start date
2016-11-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-valvular artrial fibrillation

Interventions

None listed

Sponsors

Pfizer Japan, inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Male or female subjects with age of 20 years or older 2)NVAF Patients treated with warfarin at least for 52 weeks for prevention of ischemic stroke and systemic embolism 3)Patients who have never been treated with any NOAC including apixaban

Exclusion criteria

Exclusion criteria: 1)Patients who are prescribed warfarin for treatment of disease conditions other than for prevention of cardioembolic stroke or systemic embolism. 2)Patients with valvular AF. 3)Patients without definite diagnosis of NVAF 4)Patients whose warfarin treatment is initiated within 52 weeks before the baseline.

Design outcomes

Primary

MeasureTime frame
clinical and demographic characteristics in patients(at baseline)—

Secondary

MeasureTime frame
general strategy of physician to use warfatin for treatement of non-valvular atrial patients—

Countries

Japan

Contacts

Public ContactTomomi Imai

Mebix Inc. Clinical Research Division

select@mebix.co.jp03-4362-4504

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026